- Home
- GILD vs APO Comparison
GILD vs APO Comparison
Compare GILD & APO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- APO
- Stock Information
- Founded
- GILD 1987
- APO 1990
- Country
- GILD United States
- APO United States
- Employees
- GILD N/A
- APO N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- APO Investment Managers
- Sector
- GILD Health Care
- APO Finance
- Exchange
- GILD Nasdaq
- APO Nasdaq
- Market Cap
- GILD 113.0B
- APO 98.9B
- IPO Year
- GILD 1992
- APO 2011
- Fundamental
- Price
- GILD $94.05
- APO $174.90
- Analyst Decision
- GILD Buy
- APO Buy
- Analyst Count
- GILD 26
- APO 22
- Target Price
- GILD $96.71
- APO $159.33
- AVG Volume (30 Days)
- GILD 7.2M
- APO 9.5M
- Earning Date
- GILD 02-11-2025
- APO 02-06-2025
- Dividend Yield
- GILD 3.28%
- APO 1.06%
- EPS Growth
- GILD N/A
- APO 94.60
- EPS
- GILD 0.10
- APO 9.42
- Revenue
- GILD $28,299,000,000.00
- APO $31,671,000,000.00
- Revenue This Year
- GILD $6.50
- APO N/A
- Revenue Next Year
- GILD $0.36
- APO $17.02
- P/E Ratio
- GILD $929.26
- APO $18.56
- Revenue Growth
- GILD 3.31
- APO 22.97
- 52 Week Low
- GILD $62.07
- APO $89.76
- 52 Week High
- GILD $98.90
- APO $189.49
- Technical
- Relative Strength Index (RSI)
- GILD 57.65
- APO 54.98
- Support Level
- GILD $90.27
- APO $167.39
- Resistance Level
- GILD $94.05
- APO $174.85
- Average True Range (ATR)
- GILD 1.99
- APO 5.73
- MACD
- GILD 0.07
- APO -1.24
- Stochastic Oscillator
- GILD 82.30
- APO 30.12
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About APO Apollo Global Management Inc. (New)
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Asset Management, Retirement Services, and Principal Investing. It generates maximum revenue from the Retirement Services segment.